ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 577

TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells

Naonori Hashimoto1, Kohsuke Yoshida1, Teppei Hashimoto2, Ayako Nakai1, Kenta Kaneshiro1, Kohjin Suzuki1, Yoshiko Kawasaki2, Nao Shibanuma3, Natsuko Nakagawa4, Yoshitada Sakai5 and Akira Hashiramoto6, 1Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 3Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 4Department of Orthopaedic Surgery, Konan-Kakogawa Hospital, Kakogawa, Japan, 5Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, 6Department of Biophysics, Department of Biophysics, Kobe University Graduate School of Health Sciences, Kobe, Japan

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biomarkers, DNA, Rheumatoid arthritis (RA), synovial cells, synovial fluid and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:   DNA is fragmented and released into blood circulation as a circulating cell-free DNA (ccfDNA) because of damage or death of cells. Although the lower concentration of ccfDNA is present in peripheral bloods from healthy individuals, significantly higher amount of those are detected in cancer patients or pregnant women (1). Thus, ccfDNA has recently been recognized as biomarkers of several medical conditions. In this study, we measured the amount of ccfDNA in peripheral bloods from RA patients and healthy controls, and in synovial fluid samples of knee joint from RA patients and osteoarthritis (OA) patients. Moreover, we investigated the mechanism of ccfDNA production and found that TCZ inhibited the production of ccfDNA derived from RA synovial cells.

Methods:   The amount of ccfDNA was measured by qPCR in peripheral bloods from 29 patients with RA, and 21 healthy controls., and in synovial fluid of knee joint from 13 patients with RA, and 12 patients with OA. By using human synovial cells, culture-supernatants were collected in each steps of cellular-confluency; 40% to 120%. In addition, after stimulated with interleukin(IL)6/soluble IL6 receptor(sIL6R) or TNFα, synovial cells were further treated with and without tocilizumab(TCZ: 100μg/mL) or etanercept(ETN: 10μg/mL) to collect supernatants. When examining ccfDNA in supernatants by qPCR, we amplified both short and long DNA fragments using ALU115-bp primer and ALU247-bp primer to distinguish apoptotic fragments from non-apoptotic fragments, respectively. Viabilities of synovial cells were also examined by WST-8 assay.

Results:   The amount of ccfDNA in RA patients was significantly increased as compared to healthy controls, and to OA patients. In supernatants, amounts of ccfDNA (ALU115 and ALU247) increased before 100% confluency cultured-state, and decreased after 100% confluency. Amounts of ccfDNA (ALU115 and ALU247) were significantly suppressed by TCZ treatment, while those with ETN were not changed. Notably, cellular viabilities showed no significant difference between non-treated and biological DMARDs-treated groups, and the ratio of ALU247 to ALU115 was significantly reduced by TCZ.

Conclusion:   Results clearly showed that ccfDNA was a diagnostic biomarker for RA in both peripheral blood and joint fluid, and suggesting that ccfDNA in peripheral blood was derived from synovial tissue. Another source of ccfDNA was considered to be physiological cell division because the amount of ccfDNA was increased by cell proliferation and decreased in the growth inhibition by cell-to-cell contact. Thus it appeared that TCZ inhibit the physiological cell division and the ratio of ALU247 to ALU115 could represent the therapeutic response for TCZ, since ALU115 represents the total amount of ccfDNA and ALU247 specifically represents those released by cell division. References: (1) T B Hao, et al. 2014 Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer. British Journal of Cancer 111(8):1482-9


Disclosure: N. Hashimoto, None; K. Yoshida, None; T. Hashimoto, None; A. Nakai, None; K. Kaneshiro, None; K. Suzuki, None; Y. Kawasaki, None; N. Shibanuma, None; N. Nakagawa, None; Y. Sakai, None; A. Hashiramoto, None.

To cite this abstract in AMA style:

Hashimoto N, Yoshida K, Hashimoto T, Nakai A, Kaneshiro K, Suzuki K, Kawasaki Y, Shibanuma N, Nakagawa N, Sakai Y, Hashiramoto A. TCZ Modulates the Production of Ccfdna Derived from RA Synovial Cells [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tcz-modulates-the-production-of-ccfdna-derived-from-ra-synovial-cells/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tcz-modulates-the-production-of-ccfdna-derived-from-ra-synovial-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology